Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TET3 | O43151 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | FBXL19 | Q6PCT2 | 2/20 | 0.50 |
| ▸ | CXXC5 | Q7LFL8 | 2/20 | 0.50 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.50 |
| ▸ | CXXC4 | Q9H2H0 | 2/20 | 0.50 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.50 |
| ▸ | APP | P05067 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 10/20 | 0.43 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.42 |
| ▸ | FABP7 | O15540 | 1/20 | 0.42 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL119410 | 0.92 | KMT2A (0.49) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL4879638 | 0.91 | APP (0.43) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL30089214 | 0.89 | KMT2A (0.42) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL22960725 | 0.89 | KMT2A (0.42) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL3015079 | 0.89 | KMT2A (0.42) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL5197854 | 0.86 | OPRM1 (0.47) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL4873237 | 0.85 | HSD11B1 (0.43) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL7813068 | 0.84 | KMT2A (0.42) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL6519788 | 0.81 | KMT2A (0.42) | TET3KMT2AFBXL19CXXC5KDM2B | |
| SCHEMBL28864147 | 0.79 | EPHX2 (0.44) | KMT2AFABP7FABP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
| EP-1814552-A2 | COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS | Astex Therapeutics Limited (GB) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006051290-A2 | COMPOUNDS FOR TREATING PROTEIN-KINASE MEDIATED DISORDERS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | CNKSR1, PRKCH, PRKAR2B | TET3 4377/4885KMT2A 1763/4885FBXL19 1866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.